



C/2026/1745

17.3.2026

**Prior notification of a concentration**  
**(Case M.12314 – BIOMARIN PHARMACEUTICAL / AMICUS THERAPEUTICS)**

**Candidate case for simplified procedure**

(Text with EEA relevance)

(C/2026/1745)

1. On 10 March 2026, the Commission received notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 <sup>(1)</sup>.

This notification concerns the following undertakings:

- BioMarin Pharmaceutical Inc. ('BioMarin', Unites States),
- Amicus Therapeutics Inc. ('Amicus', United States).

BioMarin will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Amicus.

The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are the following:

- BioMarin (Nasdaq: BMRN) is a global biotechnology company engaged in the research, development, manufacturing and commercialisation of pharmaceutical products for the treatment of several rare genetic diseases such as CLN2 (Batten) disease and Morquio A syndrome. BioMarin was founded in 1997 and is headquartered in San Rafael, California, United States. Further information is available at: <https://www.biomarin.com/>,
- Amicus (Nasdaq: FOLD) is a global biotechnology company specialising in the development and commercialisation of therapies for rare diseases, including Fabry disease and Pompe disease. Amicus was founded in 2002 and is headquartered in Princeton, New Jersey, United States. Further information is available at: <https://amicusrx.com/>.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

Pursuant to the Commission Notice on a simplified treatment for certain concentrations under Council Regulation (EC) No 139/2004 on the control of concentrations between undertakings <sup>(2)</sup> it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed concentration to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.12314 – BIOMARIN PHARMACEUTICAL / AMICUS THERAPEUTICS

<sup>(1)</sup> OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation').

<sup>(2)</sup> OJ C 160, 5.5.2023, p. 1.

Observations can be sent to the Commission by email or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Postal address:

European Commission  
Directorate-General for Competition  
Merger Registry  
1049 Bruxelles/Brussel  
BELGIQUE/BELGIË

---